This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Nasal Drug Development, Trends and Challenges with Nasal Formulations
Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions
Nose to Brain Drug Delivery – A Promising Future
Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation
Aptar Pharma Q&A on trends and challenges in nasal drug delivery
Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation
Why it is time to think differently about Nasal delivery of Biologics
Publications, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions
